PHARMACOLOGY ANALYTIC

药理分析

• 批准号: 8661001
• 负责人: MICHELLE A RUDEK
• 金额: $ 17.53万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-05-01 至 2017-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8661001
• 关键词: Age; Animals; Antineoplastic Agents; Archives; Area; Back; Biological Assay; Boxing; Calibration; Cancer Center Support Grant; Cell physiology; Clinical; Clinical Research; Clinical Trials Design; Comprehensive Cancer Center; Computers; Consultations; Core Facility; Coupled; Data; Data Analyses; Data Storage and Retrieval; Databases; Drug Kinetics; Ensure; Enzymes; Equipment; Equipment and supply inventories; Faculty; Floor; Fluorescence; Freezing; Funding; Grant; Health Personnel; High Pressure Liquid Chromatography; Housing; Human; Human Resources; In Vitro; Individual; Industry; Institution; Internet; Investigation; Ions; Laboratories; Laboratory Technicians; Lead; Link; Location; Maintenance; Mass Spectrum Analysis; Medical; Medical History; Methods; Mission; Monitor; NCI Center for Cancer Research; Names; Pathology; Patients; Peer Review; Pharmaceutical Preparations; Pharmacodynamics; Pharmacogenetics; Pharmacology; Plasma Cells; Positioning Attribute; Principal Investigator; Procedures; Processed Genes; Protein Binding; Protocols documentation; Published Comment; Reagent; Reporting; Research; Research Personnel; Resource Sharing; Retrieval; Running; Safety; Sampling; Secure; Services; Social Security Number; Solutions; Specialist; Specimen; Staging; Standardization; System; Temperature; Testing; Time; Tissues; Training; Validation; Visit; Water; Writing; analytical method; anticancer research; assay development; computerized data processing; cost; data acquisition; design; detector; drug metabolism; falls; gene therapy; good laboratory practice; improved; instrument; instrumentation; mass spectrometer; meetings; member; metabolic abnormality assessment; method development; microbial alkaline proteinase inhibitor; oncology; operation; preclinical evaluation; preclinical study; programs; quality assurance; queuine; research clinical testing; square foot

DESCRIPTION OF SHARED RESOURCE Since the founding of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) Analytical Pharmacology Core (APC) in 1985, the primary mission of the APC has been to enable the inclusion of critical pharmacological endpoints in the design of clinical trials and preclinical studies, and stimulate new hypotheses and areas of investigation by providing by-cost, state-of-the-art services. The APC provides state-of-the-art equipment and facilities in 1200 square feet of laboratory space on the first floor of the SKCCC Cancer Research Building (CRBI). The location of the APC is adequate to meet the needs of the SKCCC investigators to investigate the pharmacokientics, pharmacodynamics, and pharmacogenetics of anticancer agents. Services include pharmacological trial design, analytical method development and validation, pharmacokinetic and pharmacodynamic data analysis and interpretation, and consultation for design of in vitro drug metabolism, protein binding studies, non-invasive phenotypic probes for drug metabolizing enzymes, and pharmacogenetic studies. The APC houses five UPLC/HPLC instruments with a UV/fluorescence (1), triple stage quadruple mass spectrometer (3), and a QTrap system with ion trap capabilities (1) for more intricate drug metabolism studies. The APC sample analysis has steadily increased since 2005 and is analyzing more than 4,000 samples/year with 20 new methods developed/year, serving over 26 faculty members who are members of eleven CCSG Programs with the majority of the users having peer-reviewed funding. The requested CCSG funding will support personnel who provide consultative services related to assay development, protocol design, and data interpretation, and who ensure that instrumentation is suitably maintained and available for investigators seeking support from the APC Lay: The ability to quantify drugs and their metabolites in cells, plasma, and tissues is an essential need in research aimed at determining how drugs go through the body and the link to the drug's effects both in animals and in humans. The Analytical Pharmacology Core laboratory provides services to design, conduct, and interpret this data. SKCCC Managed Shared Resource Current Grant Year Reporting Period: January 1, 2010 to December 31, 2010.

自1985年Sidney Kimmel综合癌症中心（SKCCC）分析药理学核心（APC）成立以来，APC的主要使命是在临床试验和临床前研究的设计中纳入关键药理学终点，并通过提供按成本计算的最先进服务激发新的假设和研究领域。APC在SKCCC癌症研究大楼（CRBI）一楼1200平方英尺的实验室空间内提供最先进的设备和设施。APC的位置足以满足SKCCC研究者研究抗癌药物的药代动力学、药效学和药物遗传学的需要。服务包括药理学试验设计、分析方法开发和验证、药代动力学和药效学数据分析和解释、体外药物代谢设计咨询、蛋白质结合研究、药物代谢酶的非侵入性表型探针和药物遗传学研究。APC配备了五台UPLC/HPLC仪器，包括UV/荧光（1）、三级四重质谱仪（3）和具有离子阱功能的QTrap系统（1），用于更复杂的药物代谢研究。APC样品分析自2005年以来稳步增长，每年分析4,000多个样品，每年开发20种新方法，为11个CCSG项目的26名教师提供服务，其中大多数用户都有同行评审资金。申请的CCSG资金将支持提供与检测开发、方案设计和数据解释相关的咨询服务的人员，以及确保仪器得到适当维护并可供寻求APC Lay支持的研究者使用的人员：定量药物及其在细胞、血浆、在旨在确定药物如何通过人体以及药物在动物和人体中的作用之间的联系的研究中，分析药理学核心实验室提供设计、执行和解释这些数据的服务。 SKCCC托管共享资源 当前资助年度报告期：2010年1月1日至2010年12月31日。